Dr. Clay Siegall manages a blog that discusses emerging matters in the world. Most recently, he posted an article that elaborated on the consequences of recycling. This article was derived from an interview hosted by Rachel Martin who spoke to two guest speakers: Shankar Vedantam and Remi Trudel.
Insights on why people recycle
This article revealed that people recycle because they feel guilty when they waste paper products. Recycling makes people feel virtuous, and this could lead to severe outcomes. This is evident in the sense that people feel that they can overuse paper products, such as napkins because at the back of their mind they know that recycling exists. This article also revealed that people care about other practices, such as reusing and reducing. Therefore, when designing policies to govern issues about environmental conservation, it is important to pay attention to people’s feelings. This consideration is important because when people feel connected to something, they tend to care about its impact.
About Dr. Clay Siegall
Dr. Clay Siegall is the chairman of Seattle Genetics and the director of Ultragenyx Pharmaceutical. He schooled at the reputable University of Maryland and the notable George Washington University. Dr. Siegall holds a doctorate in philosophy and genetics. He is the winner of the Entrepreneur of the year award and was named the Alumnus of the year for computer, math, and natural sciences. Dr. Siegall is a qualified researcher with an in-depth interest in targeted cancer therapies.
Dr. Siegall created Seattle Genetics, a company that pioneered in the development of ADC technology. Under his leadership, Seattle Genetics has been able to obtain licenses for various products, including AbbVie, Pfizer, Genentech, and GlaxoSmithKline. This company is also involved in conducting rigorous, innovative research accompanied by the development of antibody drug conjugates. Aside from research work, Dr. Siegall has enabled the company raise more than $675 million to fund cancer research. Seattle Genetics has over 20 antibody drug conjugates, which are under development. Dr. Siegall is the director of Alder Biopharmaceuticals Inc. and Mirna Therapeutics Inc. Before forming Seattle Genetics, he rendered his expertise at Bristol-Myers. Dr. Siegall also served as a scientist at the National Cancer Institute.